All In Biotech

Drug Trial Radar · NCT02216383

Intramuscular Oxytocics: A Randomised Control Trial

Intramuscular Oxytocics: A Randomised Control Trial of Intramuscular Carbetocin, Syntocinon and Syntometrine for the Third Stage of Labour Following Vaginal Birth

Last checked: Nov 19, 2026Latest source record: Nov 14, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 5,798 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

5,798

Actual

Start

Feb 2015

Primary completion

Aug 31, 2018

Study completion Oct 30, 2018

Sponsor

Lead sponsor
North Bristol NHS TrustAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ferring Pharmaceuticals; University of Bristol; University of the West of England; Royal United Hospital Bath NHS Trust; Gloucestershire Hospitals NHS Foundation Trust; University Hospitals Bristol and Weston NHS Foundation Trust
First posted
Aug 15, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
Female only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A quarter of all pregnancy and child-birth related deaths are due to excessive bleeding after the birth, "post-partum haemorrhage" (PPH). In the UK, PPH affects approx 10% of new mothers. PPH can be frightening for women and cause them to need additional treatments prolonging their hospital stay. Commonly PPH is caused by an inadequately contracted womb after childbirth. Giving the mother an injection of "uterotonic" medicine following the birth of their baby can prevent this. It reduces the risk of PPH by 66%. In the UK, the two medicines most commonly used are Syntocinon and Syntometrine. Syntometrine is longer acting, but a published review of trials concluded that Syntometrine is no better at preventing severe blood loss. Syntometrine is associated with more side effects including nausea, vomiting, and high blood pressure, and has been linked with rare, but fatal, cases of stroke. All guidelines therefore recommend Syntocinon for preventing PPH.Following a telephone survey of all maternity units in the UK, 71.4% of units still routinely use Syntometrine. Carbetocin is a newer medicine, already widely used after caesarean section, but not yet after vaginal birth. Other studies have shown that Carbetocin is slightly better at preventing bleeding after birth when compared to Syntometrine, has fewer side effects than Syntometrine, and that it may be just as good as Syntocinon at preventing PPH. No studies have directly compared all three medicines or compared their overall cost; information vital to the NHS. Investigators propose a trial of 5712 women over 13 months, in four maternity units to compare the effectiveness, side effects and cost of Syntocinon, Syntometrine and Carbetocin, for women having a vaginal birth. Women will be randomly allocated to receive one of these drugs. Women and staff will not know which drug they receive. Staff will collect data such as the number of extra drugs and treatments needed and the volume of blood lost. Women will be asked to complete a side effects questionnaire. Investigators will perform an analysis of cost effectiveness once all results are available. Aim: To directly compare the effectiveness, side effects and cost of Syntocinon, Syntometrine and Carbetocin given intramuscularly to prevent PPH in the 3rd stage of labour.

Conditions

  • Post Partum Haemorrhage

Interventions

  • CarbetocinDrug

    The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Carbetocin, listed here, is one of the of the three study drugs.

  • SyntocinonDrug

    The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Syntocinon, listed here, is one of the of the three study drugs.

  • SyntometrineDrug

    The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Syntometrine, listed here, is one of the of the three study drugs.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Requirement for additional uterotonic drugs within 24 hours of birthTime frame: From administration of prophylactic uterotonic agent to discharge from labour ward, within an expected average of 6 hours.

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Nottingham University Hospitals NHS Trust

    Nottingham, United Kingdom

  • Great Western Hospital

    Swindon, United Kingdom

  • North Bristol NHS Trust

    Bristol, Avon, United Kingdom

  • Gloucestershire Hospitals NHS Trust

    Gloucester, Gloucestershire, United Kingdom

  • Royal United Hospital NHS Trust

    Bath, Somerset, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.